Objectives: The aim of this study was to assess the effect of combination therapy of simvastatin and carvedilol on clinical outcome in hypertensive patients with left ventricular (LV) dysfunction complicated with acute myocardial infarction (AMI) who underwent successful percutaneous coronary intervention (PCI). Methods: We studied 252 hypertensive patients with LV dysfunction [LV ejection fraction (LVEF) < 40%] complicated with AMI who underwent PCI. The patients were divided into four groups: combination (n=64), simvastatin alone (n=76), carvedilol alone (n=92), and neither treatment group (n=20). Results: At 6-month, compared with neither treatment, therapy with combination of two drugs, simvastatin alone, and carvedilol alone all significantly decreased systolic (by 13, 5, and 8 mmHg, respectively) and diastolic blood pressures (by 10, 4, and 6 mmHg). Simvastatin treatment significantly decreased the levels of LDL cholesterol and high-sensitivity C-reactive protein (hs-CRP). At 6-month after PCI, compared with baseline LVEF, it was improved by 35%, 24%, 22%, and 7% in combination group, simvastatin alone group, carvedilol alone group, and neither treatment group, respectively. During 1-year follow-up, therapy with combination of two drugs, simvastatin alone, and carvedilol alone all significantly decreased the mortality compared with neither treatment (combination: 5%, simvastatin alone: 8%, carvedilol alone: 8%, neither: 25%, p<0.05 between neither treatment and another groups). The results on major adverse cardiovascular events (MACE) showed that the combination of simvastatin and carvedilol was associated with a relative risk reduction of 54%, treatment with simvastatin alone with a relative risk reduction of 44%, and carvedilol alone with a relative risk reduction of 44% compared with neither treatment. The independent predictors of 1-year MACE were neither treatment, diabetes mellitus, elevated baseline hs-CRP (��� 0.5 mg/dl), and old age (> 70 years). Conclusions: Combination therapy with simvastatin and carvedilol had a positive impact on the end points of cardiovascular death and MACE in hypertensive patients with LV dysfunction complicated with AMI who underwent successful PCI.